Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Zacks Investment Research
SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue EstimatesSOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.
Headlines open the publisher's site.
